Terms: = Liver cancer AND KAT6A
4 results:
1. Matrix stiffness-induced upregulation of histone acetyltransferase kat6a promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract] [Full Text] [Related]
2. kat6a and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract] [Full Text] [Related]
3. kat6a is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, kat6a, as Potent Senescence-Inducing Anti-cancer Agents.
Priebbenow DL; Leaver DJ; Nguyen N; Cleary B; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Shackleford DM; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Jousset Sabroux H; Falk H; Chung MC; Hermans SJ; Downer NL; Parker MW; Voss AK; Thomas T; Baell JB
J Med Chem; 2020 May; 63(9):4655-4684. PubMed ID: 32118427
[TBL] [Abstract] [Full Text] [Related]
